Frankfurt - Delayed Quote EUR

Q32 Bio Inc. (DB0.F)

1.5300
+0.1200
+(8.51%)
At close: May 16 at 9:30:45 PM GMT+2
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for DB0.F

Recent News: DB0.F

View More
Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
PR Newswire 10 days ago
Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata

Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata
PR Newswire 18 days ago
Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata

Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata
PR Newswire last month
Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update

Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update
PR Newswire 2 months ago
Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting

Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting
PR Newswire 2 months ago
Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting

Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting
PR Newswire 2 months ago
Q32 Bio to Participate in Upcoming March Investor Conferences

Q32 Bio to Participate in Upcoming March Investor Conferences
PR Newswire 2 months ago
Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata

Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata
PR Newswire 3 months ago
Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference
PR Newswire 3 months ago
Q32 Bio price target lowered to $20 from $80 at Oppenheimer

Q32 Bio price target lowered to $20 from $80 at Oppenheimer
TipRanks 5 months ago
Investors Slaughter Q32 Bio On A 'Messy' Update In Eczema, Alopecia Treatment

Investors Slaughter Q32 Bio On A 'Messy' Update In Eczema, Alopecia Treatment
Investor's Business Daily 5 months ago
View More

Related Tickers

SCNI Scinai Immunotherapeutics Ltd.
2.9100
+5.43%
 
ELTX Elicio Therapeutics, Inc.
5.33
+0.19%
 
IVA Inventiva S.A.
3.1100
-10.12%
 
SRZN Surrozen, Inc.
7.10
+3.65%
 
IPHA Innate Pharma S.A.
2.1100
0.00%
 
ANTX AN2 Therapeutics, Inc.
1.2100
-1.63%
 
OKYO OKYO Pharma Limited
1.4800
+5.71%
 
ABVX ABIVAX Société Anonyme
6.01
+0.33%
 
VRDN Viridian Therapeutics, Inc.
12.94
+2.54%
 
MBX MBX Biosciences, Inc.
11.16
+4.79%